Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% on Analyst Downgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares fell 4% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from $124.00 to $99.00. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock. Sarepta Therapeutics traded as low as $78.68 and last traded at $76.78. 123,747 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 1,192,278 shares. The stock had previously closed at $79.97.

A number of other equities research analysts have also recently commented on SRPT. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday. HC Wainwright reissued a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Piper Sandler reduced their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $168.55.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the business. Manchester Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its holdings in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. lifted its holdings in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank boosted its stake in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics during the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm’s 50-day moving average price is $109.26 and its 200-day moving average price is $118.86. The stock has a market cap of $7.42 billion, a P/E ratio of 61.23 and a beta of 0.79.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.